Science Current Events | Science News | Brightsurf.com
 

Joslin Researchers Discover Protein that Causes Blood Vessel Leakage in Eyes with Diabetic Retinopathy

January 30, 2007
Although health professionals have had success in treating diabetic retinopathy, two forms of the disease — proliferative diabetic retinopathy and diabetic macular edema — still are the leading causes of vision loss and blindness among working age adults in the developed world. Now a Joslin Diabetes Center-led team of investigators has compiled the most complete inventory yet available of the proteins present in a part of the human eye known as the vitreous and has identified a group of proteins that may play critical roles in causing blood vessel leakage in the eyes of people with this common form of diabetic eye disease.

In the new study, published in the Jan. 28 online edition of the journal Nature Medicine, lead investigator Edward Feener, Ph.D., and his team also found that one of these molecules causes the leakage of retinal blood vessels, which contributes to the retinal swelling (diabetic macular edema or DME) that is often associated with advanced diabetic retinopathy. These findings suggest potential new therapeutic targets for the treatment of diabetic retinopathy and DME and also could provide new opportunities for treating cerebral swelling caused by head injury, stroke and other conditions.

"By analyzing the protein composition in the human vitreous (the gel fluid that fills the cavity of the eye between the lens and the retina), we have identified a new group of molecules that may improve our understanding of the disease processes that contribute to diabetic retinopathy. By studying the actions of these proteins in both the retina and the brain, we have shown that our findings may have broad relevance for neurovascular leakage and swelling," said Dr. Feener, Investigator in Joslin's Section on Vascular Cell Biology, Director of Joslin's Proteomics Core, which hosted the study, and Assistant Professor of Medicine at Harvard Medical School.

The work was funded by grants from the Juvenile Diabetes Research Foundation (JDRF), the Massachusetts Lions Eye Research Fund, the National Institutes of Health, the Adler Foundation, and the Air Force Office of Scientific Research Medical Free Electron Laser Program.

"Millions of people worldwide live with diabetic retinopathy and the accompanying threat of severe vision loss or blindness. While some treatment is available in the late stages of this condition, the incidence of proliferative diabetic retinopathy and diabetic macular edema still pose the serious threat of sight loss. Going forward, Dr. Feener's findings could provide new opportunities for the development of treatments for diabetes-related vision loss," said Dr. Helen Nickerson, Scientific Program Manager for Complications at JDRF.

Diabetic retinopathy, one of the most common complications of diabetes, is characterized by a range of abnormalities that develop from the damage caused by high blood glucose levels on the small blood vessels of the retina. Proliferative diabetic retinopathy (PDR) is diagnosed when the retina begins to form new blood vessels to counteract this damage, new vessels which in turn often bleed and blur or block vision. More than 700,000 patients in the United States have PDR, and more than 63,000 patients develop it annually. Diabetic macular edema occurs as the leaky blood vessels cause the macula (the central area in the retina responsible for sharp central vision) to swell. DME affects more than 500,000 patients in the U.S., with 56,000 new cases diagnosed yearly.

In the past, researchers have had difficulty studying the pathology of both of these diseases because rodents with diabetes, which investigators often use as a laboratory model to study diabetic eye disease, do not naturally produce many of the changes in the retina that health professionals observe in humans. Dr. Feener and his colleagues developed cutting edge proteomics mass spectroscopy (a high-speed protein analysis technology) and bioinformatics at Joslin to identify protein abnormalities in the vitreous of people with and without diabetic eye disease. Then, they introduced these same proteins in the vitreous of rodents and examined their effects on retinal blood vessels to gain better understanding of the actions that these proteins could have in the eyes of people with diabetes.

Working with a network of collaborators at Joslin's Beetham Eye Institute and the Santa Barbara Cottage Hospital Eye Center in California, they obtained samples from the vitreous of 25 people undergoing surgery for a variety of conditions: eight of the patients did not have diabetes and therefore no diabetic eye disease; four had diabetes, but no diabetic retinopathy; and 13 had PDR. Launching a large-scale survey of the proteins in the vitreous, they identified 117 proteins (earlier attempts to catalog vitreous proteins had succeeded in identifying only 20 to 50) and detected 31 proteins that were present in the vitreous of patients with diabetes but weren't present in people without the disease.

One of the proteins that was particularly interesting was carbonic anhydrase 1, or CA-1. "This is an enzyme that is normally found in red blood cells; however we suspected that high levels of this protein in the vitreous fluid might cause problems," said Dr. Feener. "When we tested it in the vitreous of rodents, we found a marked increase in blood vessel leakage, which is a fundamental process in diabetic retinopathy."

Margaret Dunn, President of the Massachusetts Lions Eye Research Fund, Inc., said, "On behalf of the Lions of Massachusetts and the Massachusetts Lions Eye Research Fund, Inc., we wish to congratulate Joslin Diabetes Center on its important breakthrough. We pledge our full support now and in the future in the hope that we will be able to contribute to many future endeavors of the Joslin research team and applaud them on their wonderful accomplishments."

The mission of the Massachusetts Lions Eye Research Fund (MLERF) is to fund efforts in eye research that may one day lead to the prevention of blindness in the world. They play a unique role in eye research efforts, enabling avenues of research to be explored as preliminary studies that may ultimately lead to remarkable breakthroughs in our understanding of the causes of blindness. In this respect, the research team at Joslin's Beetham Eye Institute led by Sven-Erik Bursell, Ph.D., and Allen Clermont, M.S., were able to use funding from the MLERF to conduct the necessary experiments to characterize the physiological effect of these proteins and how they were exerting these abnormal effects.

The researchers then investigated several different lines of study and found that CA-1 increased retinal edema—the swelling of the retina. "This is the first evidence we have of a protein causing swelling, not just leakage, in the rodent at concentrations observed in human disease," said Dr. Feener.

Performing additional studies with CA-1, the researchers showed that their findings have even broader relevance. "The eye is a neurovascular tissue with certain features similar to those of the brain, and it is well known that hemorrhage in the brain, either from a hemorrhagic stroke or any cerebral bleeding, causes swelling," said Dr. Feener. "When we introduced CA-1 into the cerebral spinal fluid around the brain of rodent animal models we found that it also increased the swelling and the leakage of blood vessels in the brain." This discovery, he explained, could provide new opportunities for treating the cerebral swelling caused by head injury, stroke and other conditions.

"Proteomics of human vitreous fluid has generated new ideas about the effects of diabetes on the retina," said Dr. Feener. "Now we are in the process of exploring the role of the other proteins we have identified in the vitreous, which may provide additional insights into the mechanisms that contribute to diabetic retinopathy."

Others participating in the study included lead author, Ben-Bo Gao, Ph.D., of Joslin; additional collaborators from the Section on Eye Research and the Beetham Eye Institute at Joslin included Lloyd Paul Aiello, M.D., Ph.D., Susan Rook, Stephanie Fonda, Ph.D., Paul G. Arrigg, M.D.; Vivek Srinivasan, M.S., Maciej Wojtkowski, Ph.D., and James Fujimoto, Ph.D., of the Massachusetts Institute of Technology; and Robert Avery, M.D., of the Santa Barbara Cottage Hospital Eye Center.

Joslin Diabetes Center


Related Diabetic Retinopathy Current Events and Diabetic Retinopathy News Articles


Scripps Research Institute scientists reveal molecular 'yin-yang' of blood vessel growth
Biologists at The Scripps Research Institute (TSRI) have discovered a crucial process that regulates the development of blood vessels. The finding could lead to new treatments for disorders involving abnormal blood vessel growth, including common disorders such as diabetic retinopathy and cancer.

New technique detects microscopic diabetes-related eye damage
Indiana University researchers have detected new early-warning signs of the potential loss of sight associated with diabetes.

Harvard scientists visualize new treatments for retinal blindness
A new report published online in The FASEB Journal may lead the way toward new treatments or a cure for a common cause of blindness (proliferative retinopathies).

Researchers collaborate to reduce effects of the aging eye
Aging gracefully may not be an option for the 40 million people worldwide who are blind or have significant visual impairment.

Experts recommend universal diabetes testing for pregnant women at first prenatal visit
The Endocrine Society today issued a Clinical Practice Guideline (CPG) to help health care professionals provide the best care to pregnant women who have diabetes.

New eye treatment effective in laboratory tests
A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute (TSRI) in La Jolla, California.

Study Explains Why Diabetic Retinopathy Is Difficult to Treat
Damage to the retina due to diabetes can be ameliorated only partially, despite treatment with the standard drug metformin.

New class of drug targets skin cancer
A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time, opening the way to new treatments for a range of conditions from skin cancers to eye diseases.

Digital tablets improve speed and ease of reading for people with moderate vision loss
People who have eye diseases that damage their central vision can regain the ability to read quickly and comfortably by using digital tablets, according to a recent study.

GEN reports on ocular therapeutics targeting the retina
Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for six to eight weeks, there is a critical need for new remedies, according to a recent issue of GEN.
More Diabetic Retinopathy Current Events and Diabetic Retinopathy News Articles

Diabetic Retinopathy: From Diagnosis to Treatment

Diabetic Retinopathy: From Diagnosis to Treatment
by David S. Boyer MD (Author), Homayoun Tabandeh MD (Author)


The most common eye disease among those with type 1 or type 2 diabetes is diabetic retinopathy and this book explains the disease, how it develops, and options for treatment. Affecting more than five million Americans, the disease is caused by damage to the tiny blood vessels of the retina as the result of uncontrolled blood sugars, and is a leading cause of blindness. Diabetic retinopathy cannot be cured, however the onset can be delayed and the risk of progression can be reduced by keeping tight controls on glucose levels and making the right lifestyle choices. This guide will help both patients and their families by covering such topics as symptoms, stages of the disease, how it is diagnosed, treatment options, ways to slow its progression, and lifestyle changes that lead to better...

Diabetic Retinopathy: Evidence-Based Management

Diabetic Retinopathy: Evidence-Based Management
by David J. Browning (Editor)


Contains information from the Diabetic Retinopathy Clinical Research network not to be found in other published works Evidence-based approach includes material labeled with level of supporting evidence and many clinical examples Includes discussions of area of controversy

Diabetic Retinopathy (Contemporary Diabetes)

Diabetic Retinopathy (Contemporary Diabetes)
by Elia Duh (Editor)


Diabetic retinopathy is the most common microvascular complication of diabetes. It remains a major cause of new-onset visual loss in the United States and other industrialized nations. In Diabetic Retinopathy, Elia Duh and a panel of internationally recognized experts comprehensively assess the current state of knowledge regarding the clinical management of DR as well as its underlying mechanisms. The authors outline the current understanding of diabetic retinopathy from the perspective of clinical practice, while reviewing the multi-factorial pathogenesis and pathophysiology of DR from the standpoint of biomedical research. Also included is a discussion of emerging concepts relating to the management and treatment of DR. Informative and highly-practical, Diabetic Retinopathy provides...

Diabetic Retinopathy

Diabetic Retinopathy
by Jose Cunha-Vaz (Author)


This book addresses diabetic retinopathy, an eye disease that remains one of the main causes of vision loss if not diagnosed and managed properly. It aims to cover the entire spectrum of the disease by describing its clinical identification and characterization, pathophysiology, epidemiology, and medical and surgical management. Diabetic Retinopathy also offers a complete overview of the present understanding of diabetic retinopathy, covering current practice but also including original contributions that offer novel perspectives for looking at and addressing this disease. The author has dedicated his lifetime to the study of diabetic retinal disease and has organized this book around his personal experience but at the same time giving the necessary information for updated management of...

Diabetic Retinopathy: The Essentials

Diabetic Retinopathy: The Essentials
by Gloria Wu MD (Author)


Diabetic Retinopathy: The Essentials is written for general ophthalmologists and optometrists as well as family practitioners, diabetologists, and internists who encounter diabetic patients on a daily basis. It focuses on the diagnosis and management of diabetic retinopathy from the point of view of the retinal specialist. The book begins with the epidemiology, anatomy, and pathophysiology of diabetic retinopathy, and then covers important topics such as classification issues, diagnostic testing, examination techniques, new treatment modalities, patient management, indications for vitrectomy, pregnancy concerns, and informed consent. Coverage includes both general medical issues in diabetes and specifically ophthalmologic concerns. Features include more than 200 full-color photographs,...

Diabetic Retinopathy (Jaypee Gold Standard Mini Atlas)

Diabetic Retinopathy (Jaypee Gold Standard Mini Atlas)
by Sandeep Saxena (Author), Carsten H. Meyer (Foreword)


This mini atlas is a comprehensive guide to the latest developments and current concepts in diabetic retinopathy. Complemented by a photo CD, the book brings readers fully up to date with diagnostic and treatment approaches to this progressive disease. Beginning with an introduction to the epidemiology and pathogenesis of the disease, the text then discusses diagnosis techniques such as optical coherence tomography and fluorescein angiography. The following chapters examine surgical techniques including vitreoretinal surgery, laser hyaloidotomy and laser photocoagulation.

Diabetic Retinopathy: Causes, Tests, and Treatment Options

Diabetic Retinopathy: Causes, Tests, and Treatment Options
by Dale Carter MA (Author), Edward Montgomery (Editor)


Diabetes mellitus is a disease that is rapidly increasing in prevalence worldwide, particularly in Canada and the United States. One of the most common complications for all types of diabetes mellitus is diabetic retinopathy, a disease that is currently the leading cause of blindness among adults in the United States and Canada. It is estimated that at least 40% of Americans and Canadians with diabetes mellitus have some clinically detectable form of diabetic retinopathy, and statistics are similar worldwide. This invaluable book contains all the information you need to know about the causes, tests and treatment options available to combat this sight-threatening disorder.

Diagnosis and Treatment of Diabetic Retinopathy

Diagnosis and Treatment of Diabetic Retinopathy
by Boyd S. (Author)


This exciting publication on Diabetic Retinopa-thy compiles the whole concept of the disease from its initial evaluation to the most revolutionary man-agement performed today, being our main approach oriented to doctor-patient. This volume presents the understanding and the visual implications on diabetic retinopathy and the progress with the screening, as well as ocular digital evaluations, treatment and man-agement of complications. Each chapter covers explicit, detailed and most up-dated information to orient general ophthalmologists as well as vitreoretinal specialists in the current stan-dards of patients' care. Special features in each chapter include pitfalls and special considerations on practical and useful information for the diagnosis and treatment of diabetic retinopathy....

The End of Diabetes: The Eat to Live Plan to Prevent and Reverse Diabetes

The End of Diabetes: The Eat to Live Plan to Prevent and Reverse Diabetes
by Joel Fuhrman (Author)


The New York Times bestselling author of Eat to Live and Super Immunity and one of the country’s leading experts on preventive medicine offers a scientifically proven, practical program to prevent and reverse diabetes—without drugs.At last, a breakthrough program to combat the rising diabetes epidemic and help millions of diabetics, as well as those suffering with high blood pressure and heart disease. Joel Fuhrman, M.D. Research director of the Nutritional Research Foundation, shows you how to live a long, healthy, and happy life—disease free. He offers a complete health transformation, starting with a diet with a high nutrient-per-calorie ratio that can be adapted for individual needs.Dr. Fuhrman makes clear that we don’t have to “control” diabetes. Patients can choose to...

Diabetic Retinopathy for the Comprehensive Ophthalmologist

Diabetic Retinopathy for the Comprehensive Ophthalmologist
by Jonathan D. Walker (Author), Lauren Fath (Editor), M. Walt Keys (Editor)


This book is designed to transfer useful skills for the clinical management of diabetic patients. The target audience is residents, beginning retina fellows and comprehensive ophthalmologists interested in fine-tuning their approach to diabetic retinopathy. Further information and sample downloads of the book are available at drcobook.com. Please note that the book is now 3 years old--it covers the basics but not the most recent data. A second edition is planned for next year.

© 2014 BrightSurf.com